Nitrogen Mustard Therapy

Goodman, Louis S.

doi:10.1001/jama.1946.02870380008004

Cited by 536 publications

(69 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Primary cancer prevention, particularly chemoprevention, could become an increasingly useful strategy in the fight against cancer (1). Fifty years have passed since the first chemotherapeutic alkylating agent was developed, and more than a hundred clinical chemotherapeutic regimens have been developed (2,3). Nevertheless, the total number of new cancer patients worldwide in 1985 was estimated to be 7.62 million (4).…”

Section: Introductionmentioning

confidence: 99%

Anticarcinogenic Effect of Panax ginseng C.A. Meyer and Identification of Active Compounds

Yun¹,

Lee²,

Lee³

et al. 2001

J Korean Med Sci

206

138

View full text Add to dashboard Cite

The failure to improve the five-year survival rate of cancer patients, from one in three in the 1960s to one in two in the 1970s, stimulated awareness of the importance of primary prevention of cancer. Korean investigators carried out extensive long-term anticarcinogenicity experiments with 2000 newborn mice to investigate whether Panax ginseng C.A. Meyer inhibited carcinogenesis induced by several chemical carcinogens in 1978. There was a 22% decrease (p <0.05) in the incidence of urethane induced lung adenoma by the combined use of red ginseng extract. In the group sacrificed at 56 weeks after the treatment with aflatoxin B1, the incidence of hepatoma significantly decreased to 75% by the addition of red ginseng extract (p <0.05). The result showed that natural products can provide hope for human cancer prevention. By the newly established '9 week mediumterm anticarcinogenicity test model of lung tumors in mice' (Yun' s model), we confirmed significant anticarcinogenic effects of powders and extracts of the 6-yr-old dried fresh ginseng, 5-and 6-yr old white ginsengs, and 4-, 5-, and 6-yr old red ginseng. We also demonstrated that the anticarcinogencity of ginseng was more prominent in aged or heat treated extracts of ginseng and red ginseng made by steaming. To investigate the active components for cancer prevention, several fractions of 6-yr old fresh ginseng and red ginseng, four semi-synthetic ginsenoside Rh1, Rh2, Rg3 and Rg5, major saponin components in red ginseng, were prepared. Among the ginsenosides, Rg3 and Rg5 showed statistically significant reduction of lung tumor incidence and Rh2 had a tendency of decreasing the incidence. Ginsenoside Rg3, Rg5 and Rh2 were found to be active anticarcinogenic compounds. Rg3, Rg5 and Rh2 are active components in red ginseng, and they prevent cancer either singularly or synergistically.

show abstract

Section: Introductionmentioning

confidence: 99%

Anticarcinogenic Effect of Panax ginseng C.A. Meyer and Identification of Active Compounds

Yun¹,

Lee²,

Lee³

et al. 2001

J Korean Med Sci

206

138

View full text Add to dashboard Cite

show abstract

“…After an initial regression of the disease, a second course of therapy was given at a reduced dose due to the toxicity of the treatment, with an associated lesser therapeutic effect. By the time the third treatment was given, the tumour no longer responded to the chemotherapeutic agent (Goodman et al, 1946). Since then, chemotherapy has been one of the main therapeutic strategies in cancer treatment, but, to paraphrase Paul Ehrlich, resistance has followed as a faithful shadow.…”

mentioning

confidence: 99%

Resistance to chemotherapy: new treatments and novel insights into an old problem

2008

View full text Add to dashboard Cite

Resistance to cancer chemotherapeutic treatment is a common phenomenon, especially in progressive disease. The generation of cellular models of drug resistance has been pivotal in unravelling the main effectors of resistance to traditional chemotherapy at the molecular level (i.e. intracellular drug inactivation, detoxifying systems, defects in DNA repair, apoptosis evasion, membrane transporters and cell adhesion). The development of targeted therapies has also been followed by resistance, reminiscent of an evolutionary arms race, as exemplified by imatinib and other BCR-ABL inhibitors for the treatment of chronic myelogenous leukaemia. Although traditionally associated with the last stages of the disease, recent findings with minimally transformed pretumorigenic primary human cells indicate that the ability to generate drug resistance arises early during the tumorigenic process, before the full transformation. Novel technologies, such as genome profiling, have in certain cases predicted the outcome of chemotherapy and undoubtedly have tremendous potential for the future. In addition, the novel cancer stem cell paradigm raises the prospect of cell-targeted therapies instead of treatment directed against the whole tumour.

show abstract

“…Kolejnym krokiem było testowanie iperytów, najpierw na myszach, a następnie w latach 40., na pacjentach cierpiących na chłoniaki (lecz nie na chorobę Hodgkina). Autorzy tych badań przewidywali wyniki autopsji: hipoplazji limfatycznej i mielosupresji u żołnierzy z okresu I wojny światowej, narażonych na działanie gazu musztardowego [69,70]. W piśmiennictwie można znaleźć również prace na temat innych badań podjętych w latach 40., m.in.…”

Section: Kalendariumunclassified

Wybrane wydarzenia w historii medycyny, ze szczególnym uwzględnieniem zagadnień związanych z rakiem. Część 4: Od Theodora van Frerichsa (1819–1885) do Ernsta Neumanna (1834–1918)

Mould

2014

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Niniejsze zestawienie chronologiczne stanowi wybór znaczących wydarzeń w historii medycyny bezpośrednio lub pośrednio związanych z chorobą nowotworową. Przyczynkiem do powstania tego opracowania był fakt, że ukazało się dotychczas stosunkowo niewiele chronologii dotyczących historii onkologii, a spośród tych opublikowanych wiele nie ma przywołanych źródeł i nie przytacza lat życia lekarzy, chirurgów i naukowców. Autor ma zatem nadzieję, że poniższy uporządkowany w czasie i opatrzony bibliografią wybór wydarzeń i postaci będzie szczególnie pomocny dla wszystkich, którzy bardziej szczegółowo piszą o historii medycyny, a o historii onkologii w szczególności. Annotated Biographical Bibliography with Special Reference to Cancer Part 4 From Theodor van Frerichs (1819-1885) to Ernst Neumann (1834-1918)This chronology is a selection of important events in the history of medicine which are directly or indirectly related to neoplastic disease. The reason underlying its compilation is that relatively few chronologies concerning oncology have previously been published and those that do exist do not always quote references or provide the dates of birth and death of the physicians, surgeons and scientists mentioned. It is hoped that this selected chronology will be of help to those writing in depth about the history of medicine and in particular about cancer.

show abstract

Nitrogen Mustard Therapy

Cited by 536 publications

References 1 publication

Anticarcinogenic Effect of Panax ginseng C.A. Meyer and Identification of Active Compounds

Anticarcinogenic Effect of Panax ginseng C.A. Meyer and Identification of Active Compounds

Resistance to chemotherapy: new treatments and novel insights into an old problem

Wybrane wydarzenia w historii medycyny, ze szczególnym uwzględnieniem zagadnień związanych z rakiem. Część 4: Od Theodora van Frerichsa (1819–1885) do Ernsta Neumanna (1834–1918)

Contact Info

Product

Resources

About